Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.53 |
| ▸ | PPARG | P37231 | 11/20 | 0.53 |
| ▸ | PPARD | Q03181 | 5/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | IL1RN | P18510 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691428 | 0.90 | PPARA (0.52) | PPARAPPARGPPARD | |
| SCHEMBL5689426 | 0.90 | PPARA (0.61) | PPARAPPARGPPARD | |
| SCHEMBL5992953 | 0.81 | PPARG (0.63) | PPARAPPARGPPARD | |
| SCHEMBL6092840 | 0.81 | PPARA (0.61) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL3104768 | 0.81 | PPARA (0.61) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL3115791 | 0.81 | PPARA (0.61) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL3941341 | 0.79 | PPARA (0.60) | PPARAPPARGPPARD | |
| SCHEMBL5993720 | 0.79 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL6092981 | 0.79 | PPARA (0.51) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL6092773 | 0.79 | PPARA (0.51) | PPARAPPARGPPARDESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199857-A1 | Therapeutic agents | ASTRAZENECA UK LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199857-A1 | Therapeutic agents | PNLIP, LIPC, GPR119 | PPARA 27/4885PPARG 38/4885PPARD 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.